gdc
PSS Guide 2023
Bladder CancerFinancial Support

Drugs for Bladder Cancer (Urothelial Carcinoma)

Find financial assistance programs available for bladder cancer drugs.

Balversa (erdafitinib)

Drug company: Janssen
866-378-1910

Janssen offers 2 financial assistance programs for patients who have been prescribed Balversa:

Janssen CarePath Savings Program

Johnson & Johnson Patient Assistance Foundation

Bavencio (avelumab)

Drug company: EMD Serono
844-826-8371

EMD Serono offers 2 financial assistance programs for patients using Bavencio:

CoverOne Co-Pay Assistance Program

CoverOne Patient Assistance Program

Jelmyto (mitomycin)

Drug company: UroGen Pharma
855-535-6986

UroGen Support offers 2 financial assistance programs for patients who have been prescribed Jelmyto:

UroGen Support Copay Program

UroGen Support Patient Assistance Program

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Merck Patient Assistance Program

Opdivo (nivolumab)

Drug company: Bristol Myers Squibb
800-861-0048

Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:

BMS Oncology Co-Pay Assistance Program

Bristol Myers Squibb Patient Assistance Foundation

Padcev (enfortumab vedotin-ejfv) Injection

Drug company: Astellas/Seagen
888-472-3238

Astellas and Seagen offer 2 financial assistance programs for patients using Padcev:

Padcev Copay Assistance Program

Padcev Patient Assistance Program

Tecentriq (atezolizumab)

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial assistance programs for patients using Tecentriq:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Trodelvy (sacituzumab govitecanhziy) Injection

Drug company: Gilead
844-876-3358

Gilead, through Trodelvy Access Support, offers 2 financial assistance programs for patients using Trodelvy:

Trodelvy Savings Program

Gilead Patient Assistance Program

Table. Drugs Prescribed for Bladder Cancer (Urothelial Carcinoma)

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Bavencio (avelumab)
  • Drug company
  • EMD Serono
  • Indications
  • Treatment of locally advanced or metastatic bladder cancer that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy

    Maintenance treatment of locally advanced or metastatic bladder cancer that has not progressed with first-line platinumcontaining chemotherapy
  • Patient support services
  • CoverOne Co-Pay Assistance Program
    844-826-8371

    CoverOne Patient Assistance Program
    844-826-8371


    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indications
  • Treatment of patients with locally advanced or metastatic bladder cancer who are not eligible for platinum-containing therapy and whose tumors express PD- L1, as determined by an FDAapproved test

    Treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

    Treatment of patients with Bacillus Calmette-Guérin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932

    Drug name (generic name)
  • Opdivo (nivolumab)
  • Drug company
  • Bristol Myers Squibb
  • Indications
  • Treatment of locally advanced or metastatic bladder cancer that progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-based chemotherapy

    Adjuvant treatment of patients with bladder cancer who are at high risk of recurrence after undergoing radical resection (surgical removal) of the tumor
  • Patient support services
  • BMS Oncology Co-Pay Assistance Program
    800-861-0048

    Bristol Myers Squibb Patient Assistance Foundation
    800-736-0003

    Drug name (generic name)
  • Padcev (enfortumab vedotin-ejfv) Injection
  • Drug company
  • Astellas/Seagen
  • Indication
  • Treatment of locally advanced or metastatic bladder cancer after treatment with a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting
  • Patient support services
  • Padcev Copay Assistance Program
    888-402-0627

    Padcev Patient Assistance Program
    888-402-0627

    Drug name (generic name)
  • Tecentriq (atezolizumab)
  • Drug company
  • Genentech
  • Indication
  • Treatment of locally advanced or metastatic bladder cancer in patients who are not eligible for cisplatin-containing therapy, and whose tumors express PD-L1, as determined by an FDA-approved test

    Treatment of patients who are not eligible for any platinum-containing chemotherapy, regardless of PD-L1 status
  • Patient support services
  • Genentech Oncology Co-pay Assistance Program
    855-692-6729

    Genentech Patient Foundation
    888-941-3331

    Drug name (generic name)
  • Trodelvy (sacituzumab govitecan-hziy) Injection
  • Drug company
  • Gilead
  • Indication
  • Treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor
  • Patient support services
  • Trodelvy Savings Program
    844-876-3358

    Gilead Patient Assistance Program
    844-876-3358
Last modified: March 9, 2023

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to Conquer: the journey informed

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests